Compare NSPR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | HOWL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 46.7M |
| IPO Year | 2009 | 2021 |
| Metric | NSPR | HOWL |
|---|---|---|
| Price | $0.46 | $0.98 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | 108.5K | ★ 514.3K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,310,000.00 | N/A |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $105.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.27 |
| 52 Week High | $2.41 | $1.83 |
| Indicator | NSPR | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 24.56 | 60.91 |
| Support Level | N/A | $0.86 |
| Resistance Level | $1.00 | $0.99 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.19 | 73.79 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.